Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04691713
Status:
UNKNOWN
Last Update Posted:
2020-12-31
First Post:
2020-12-07
Brief Title:
CD276 CAR-T for Patients With Advanced CD276 Solid Tumors
Sponsor:
PersonGen BioTherapeutics Suzhou Co Ltd
Organization:
PersonGen BioTherapeutics Suzhou Co Ltd
Study Overview
Official Title:
CD276 CAR-T for Patients With Advanced CD276 Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a clinical study of CD276 CAR-T in the treatment of patients with advanced solid tumors The purpose is to evaluate the safety and effectiveness of targeting CD276 auto-chimeric antigen receptor T cells in the treatment of CD276-positive advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None